DA MEDSCAPE: Troy Brown, RN

February 25, 2014

US Food and Drug Administration (FDA) advisory panels have voted (18 no, 6 yes, 1 no vote) not to recommend over-the-counter (OTC) marketing of epinephrine inhalation aerosol 125 microgram (mcg)/actuation (E004; proposed trade namePrimatene HFA, Armstrong Pharmaceuticals, Inc), for temporary relief of mild symptoms of intermittent asthma for people aged 12 years or older.

The vote was taken at a joint meeting of the FDA's Nonprescription Drugs Advisory Committee and the Pulmonary-Allergy Drugs Advisory Committee.